19-4497
メトロニダゾール
SAJ first grade, ≥99.0%
別名:
2-メチル-5-ニトロイミダゾール-1-エタノール
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C6H9N3O3
CAS番号:
分子量:
171.15
EC Number:
207-136-1
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
611683
MDL number:
Assay:
≥99.0%
Grade:
SAJ first grade
InChI key
VAOCPAMSLUNLGC-UHFFFAOYSA-N
InChI
1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
SMILES string
CC1=NC=C([N+]([O-])=O)N1CCO
grade
SAJ first grade
assay
≥99.0%
form
solid
availability
available only in Japan
dilution
(for analytical testing)
mp
159-161 °C (lit.)
antibiotic activity spectrum
Gram-negative bacteria, parasites
mode of action
DNA synthesis | interferes
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
化学構造：イミダゾール
signalword
Danger
hcodes
Hazard Classifications
Carc. 1B - Muta. 1B - STOT RE 2
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
19-4497-2-25G-J:
jan
Jayaram Lakshmaiah Narayana et al.
Oncotarget, 6(15), 12936-12954 (2015-05-24)
Helicobacter pylori infection is marked by a strong association with various gastric diseases, including gastritis, ulcers, and gastric cancer. Antibiotic treatment regimens have low success rates due to the rapid occurrence of resistant H. pylori strains, necessitating the development of
Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）